Biogen, Eisai say injectable Alzheimer’s therapy granted FDA review
Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) ...
Alzheimer’s drugs eyed as next big obesity-like opportunity
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Rolling Out9d
5 ways this cancer drug could revolutionize Alzheimer’s treatment
Groundbreaking research reveals how a cancer drug could restore brain function in early Alzheimer's patients by targeting glucose metabolism. Here's what you need to know.
Alzheimer’s Drug Study Yields Mixed Results. Wall Street Still Likes Axsome.
In one study, the company’s drug eased the agitation for Alzheimer’s patients. In a different study, there wasn’t a ...
Knowridge2d
Common drugs may affect memory function
The findings were alarming. People who took at least one anticholinergic drug had a 47% higher risk of developing memory ...
FDA Accepts Eisai And Biogen's BLA For Subcutaneous LEQEMBI For Early Alzheimer's Disease
Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) said that the U.S. Food and Drug Administration has accepted Eisai's Biologics ...
Discovery of new fungi compound leads to hope for potential dementia, Parkinson’s and depression drug
A new drug to potentially treat depression and neurodegenerative diseases, such as dementia or Parkinson’s, is being ...
Cassava Sciences issues layoffs, regroups after failed drug study
An Austin biotech company is laying off a third of its staff following news that its primary drug candidate didn't produce ...
China Medical System （00867）Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer’s Type
As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
Yahoo Finance4d
Alzheimer’s Drugs Eyed as Next Big Obesity-Like Opportunity
Firms developing Alzheimer’s drugs have already seen big peaks and troughs. Biogen shares soared 44% on a single day in November 2020 after news that an experimental drug appeared to be ...